Olipudase Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HAS (France), among others, recommended or restricted olipudase alfa, while PBAC (Australia) did not recommend it.
The record spans 2.1 years, opening at AWMSG (Wales) on 26 Jul 2022 and running to 21 Aug 2024.
CIPM (Spain) changed its position: not recommended on 23 Oct 2023, recommended by 24 Apr 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 9 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for olipudase alfa by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess olipudase alfa, on 26 Jul 2022; ZIN (Netherlands) did not open a file until 21 Aug 2024 — a moderate spread of 2.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 11 dated records fall in 2023 alone.
CIPM (Spain) is the only agency to have returned to olipudase alfa, recording 4 separate entries.
8 of the 18 agencies in this archive hold a record for olipudase alfa.
The full ledger for olipudase alfa reads 4 recommended, 4 not recommended, 1 other and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 21 Aug 2024 | Advies - vergoed olipudase alfa (Xenpozyme®) voor de behandeling van de ziekte van Niemann-Pick | reimbursed | source |
| CIPM (Spain) | 29 Jan 2024 | Indicación terapéutica autorizada : Xenpozyme está indicado como terapia enzimática de sustitución para el tratamiento d… | not financed by the SNS (financed 2024-04) | source |
| AIFA (Italy) | 25 Nov 2023 | XENPOZYME è indicato, in pazienti pediatrici e adulti, come terapia enzimatica sostitutiva per il trattamento delle mani… | fully innovative · reimbursed class H | source |
| SMC (Scotland) | 11 Sep 2023 | As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult p… | unknown | source |
| PBAC (Australia) | 2023 | Acid sphingomyelinase deficiency (ASMD) | Not Recommended | source |
6 further decisions for olipudase alfa, across 4 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 11 decisions for olipudase alfa from 8 agencies, 2022 to 2024. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.